INT15687

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1991
Last Reported 2011
Negated 5
Speculated 8
Reported most in Body
Documents 91
Total Number 99
Disease Relevance 40.42
Pain Relevance 7.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (ESR1) enzyme binding (ESR1) DNA binding (ESR1)
protein complex (ESR1) cytoplasm (ESR1) signal transduction (ESR1)
Anatomy Link Frequency
uterine 5
joint 3
MCF-7 2
uterus 2
neurons 2
ESR1 (Homo sapiens)
ESR1 - G594A (1)
Pain Link Frequency Relevance Heat
agonist 357 99.84 Very High Very High Very High
Serotonin 15 99.56 Very High Very High Very High
Arthritis 92 99.40 Very High Very High Very High
Migraine 39 99.08 Very High Very High Very High
Dopamine 23 98.96 Very High Very High Very High
Pain 95 98.74 Very High Very High Very High
Etanercept 190 98.48 Very High Very High Very High
cINOD 52 98.40 Very High Very High Very High
Inflammation 211 97.76 Very High Very High Very High
visual analogue scale 7 97.60 Very High Very High Very High
Disease Link Frequency Relevance Heat
Polymyalgia Rheumatica 79 100.00 Very High Very High Very High
Stress 329 99.96 Very High Very High Very High
Arthropathy 4 99.84 Very High Very High Very High
Noninfiltrating Intraductal Carcinoma 39 99.72 Very High Very High Very High
Breast Cancer 1180 99.68 Very High Very High Very High
Cancer 1082 99.60 Very High Very High Very High
Arthritis 74 99.40 Very High Very High Very High
Death 205 99.12 Very High Very High Very High
Hyperplasia 36 99.12 Very High Very High Very High
Headache 82 99.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
ESR and CRP levels did not change, but serum MMP-3 levels decreased in the glucosamine group.
Neg (not) Regulation (change) of ESR
1) Confidence 0.60 Published 2007 Journal Rheumatol. Int. Section Abstract Doc Link 16953394 Disease Relevance 0.34 Pain Relevance 0.30
Novel agents that target ER?
Regulation (target) of ER
2) Confidence 0.57 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0.66 Pain Relevance 0.17
There is presently no direct evidence that progestins regulate the concentration of estrogen receptors (ER) in normal breasts.
Neg (no) Regulation (regulate) of ER
3) Confidence 0.53 Published 1995 Journal Arch. Anat. Cytol. Pathol. Section Abstract Doc Link 7794024 Disease Relevance 0.42 Pain Relevance 0.09
To determine whether decursin and DA affected the ER?
Spec (whether) Regulation (affected) of ER
4) Confidence 0.50 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0 Pain Relevance 0
We have previously reported a role for the ESR1 G594A polymorphism in migraine susceptibility.
Regulation (role) of ESR1 (G594A) associated with migraine
5) Confidence 0.44 Published 2006 Journal BMC Med Genet Section Body Doc Link PMC1431511 Disease Relevance 0.62 Pain Relevance 0.66
These conflicting results necessitate further investigation into the effects of acute phase reactants such as ESR and CRP on changes in the levels of serum cystatin C.
Spec (investigation) Regulation (effects) of ESR
6) Confidence 0.44 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2800003 Disease Relevance 0.50 Pain Relevance 0.08
We subsequently focused on elucidating the mechanisms by which the effective compounds affected ER?
Regulation (affected) of ER
7) Confidence 0.42 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0 Pain Relevance 0.04
Overall, these data indicate that ibandronate completely blocks the proliferative response induced by E2, without affecting ER regulation and activity.
Regulation (regulation) of ER
8) Confidence 0.41 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413981 Disease Relevance 0 Pain Relevance 0.03
Influence of ibandronate on the mitogenic effect of E2, and on estrogen receptor regulation and activity in MCF-7 cells
Regulation (regulation) of estrogen receptor in MCF-7
9) Confidence 0.41 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413981 Disease Relevance 0.20 Pain Relevance 0
Loss of progesterone activity may result in the persistence of ER-alpha, since down-regulation of ER is one of the primary actions of progesterone.
Regulation (regulation) of ER
10) Confidence 0.40 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1679803 Disease Relevance 0.70 Pain Relevance 0.19
What might account for the aberrant down-regulation of ER-alpha by the time of implantation in all of these different disorders?
Regulation (regulation) of ER
11) Confidence 0.40 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1679803 Disease Relevance 0.57 Pain Relevance 0.19
In LPD, the timing of ER-alpha down-regulation is delayed, perhaps due to inadequate progesterone levels in the serum [36].
Regulation (regulation) of ER
12) Confidence 0.40 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1679803 Disease Relevance 0.53 Pain Relevance 0.17
0.5|) genes with a frequency different in ER- and ER+ ERBB2-amplified BCs (Fisher exact test p ?
Regulation (different) of ER
13) Confidence 0.36 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.09 Pain Relevance 0
Ibandronate alone had no effect on ER content whereas E2 induced a marked receptor down-regulation reflected by a 63% decline in ER steady-state level after 24 h (Fig. 6a).
Regulation (effect) of ER
14) Confidence 0.36 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413981 Disease Relevance 0 Pain Relevance 0
Studies have also targeted the selective estrogen receptor down-regulator (SERD) fulvestrant, which indirectly inhibits growth factor pathways by down-regulating ER [3].
Regulation (regulating) of ER
15) Confidence 0.34 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.28 Pain Relevance 0
Clinical context for ER niacin–simvastatin use
Regulation (context) of ER
16) Confidence 0.32 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672455 Disease Relevance 1.44 Pain Relevance 0.10
Changes in the ESR and CRP between Before and After the Etanercept Treatment
Regulation (Changes) of ESR associated with etanercept
17) Confidence 0.31 Published 2010 Journal Clinics in Orthopedic Surgery Section Body Doc Link PMC2824092 Disease Relevance 0.11 Pain Relevance 0.15
In this study, changes in the ESR and CRP levels were observed to assess the improvement in chronic inflammation.
Regulation (changes) of ESR associated with inflammation
18) Confidence 0.31 Published 2010 Journal Clinics in Orthopedic Surgery Section Body Doc Link PMC2824092 Disease Relevance 0.70 Pain Relevance 0.40
By contrast, antiestrogens did not affect the proliferation of the ER-negative MDA-MB-231 cells, and they did not change the growth inhibitory effect of ibandronate (Fig. 7, lower panel).
Regulation (affect) of ER in MDA-MB-231
19) Confidence 0.30 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413981 Disease Relevance 0.09 Pain Relevance 0.11
and promoted the association of cofactor proteins, thereby regulating downstream ER-?
Regulation (regulating) of ER
20) Confidence 0.27 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC400678 Disease Relevance 0.22 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox